Management of advanced renal cell carcinoma / 国际外科学杂志
International Journal of Surgery
;
(12): 328-331, 2010.
Artículo
en Chino
| WPRIM
| ID: wpr-389592
ABSTRACT
Radiotherapy and chemotherapy have little or no effect on advanced renal cell carcinoma, leading to a poor prognosis. Several factors couLd affect the survival rate of RCC. Some RCC patients could partly respond to immunotherapy.The newly emerging targeted therapy has a dramatic tuning point in improving outcomes for RCC. Further understanding of the anti-RCC mechanisms involves in chemokine-mediated angiogenesis and RCC cell proliferation. These new agents include Sorafenib, Sunitinib, Temsirolimus, Bevacizumab, etc. Combination treatment with immunotherapy may lead to improved outcomes in this disease.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio pronóstico
Idioma:
Chino
Revista:
International Journal of Surgery
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS